Specialty Generics Global Market Report 2024 - By Share, Growth, Size And Demand, Forecast To 2033

"The new report published by The Business Research Company, titled ""Specialty Generics Global Market Report 2024 - Market Size, Trends, And Global Forecast 2024-2033"", delivers an in-depth analysis of the leading size and forecasts, investment opportunities, winning strategies, market drivers and trends, competitive landscape, and evolving market trends.

As per the report, the specialty generics market size has grown rapidly in recent years. It will grow from $85.85 billion in 2023 to $96.94 billion in 2024 at a compound annual growth rate (CAGR) of 12.9%. The specialty generics market size is expected to see rapid growth in the next few years. It will grow to $164.57 billion in 2028 at a compound annual growth rate (CAGR) of 14.1%.

Download Free Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=7781&type=smp

Surge In Chronic Diseases Spurs Demand For Specialty Generics Market
The surge in chronic diseases is expected to propel the demand for the specialty generic market. Chronic diseases are long-lasting sicknesses that often cannot be healed. However, it is occasionally curable and controllable. The changing lifestyle, eating habits, and not maintaining body weight are the reason for chronic conditions; a few more prolonged chronic infections lead to cancerous risk. Growing exposure to these diseases raises the need for specialty generic for a patient to treat complex chronic diseases. For instance, in September 2022, according to the World Health Organization, a Switzerland-based specialized agency of the United Nations, there were 41 million deaths, which is 74% of those caused by non-communicable diseases (NCDs) or chronic diseases every year globally. There were 17.9 million deaths from cardiovascular diseases, 9.3 million deaths from cancer, 4.1 million deaths from chronic respiratory diseases, and 2.0 million deaths from diabetes. Therefore, the surge in chronic diseases is driving the specialty generic market growth.

New Approval To Address The Critical Need For Medication
Major companies operating in the specialty generic market are receiving approval such as Lisdexamfetamine Dimesylate to address the critical need for medication. Approval in specialty generics refers to the regulatory authorization granted to pharmaceutical products that are bioequivalent and therapeutically equivalent to brand-name specialty drugs, typically used in the treatment of complex or rare medical conditions, after the expiration of their patent protection. For instance, in August 2023, Mallinckrodt plc, an Ireland-based specialty pharmaceutical company, received FDA approval for its Lisdexamfetamine Dimesylate Capsules in SpecGx LLC Specialty Generics segment, to treat Attention-Deficit/Hyperactivity Disorder (ADHD). . Lisdexamfetamine Dimesylate is a type of specialty generic, and a federally controlled substance (CII) used to treat ADHD and other indications .

The specialty generics market covered in this report is segmented -
1) By Route Of Administration: Injectables, Oral, Other Route Of Administration
2) By Indication: Oncology, Autoimmune Diseases, Infectious Diseases, Other Indication
3) By Distribution Channel: Retail Pharmacies, Specialty Pharmacies, Hospital Pharmacies

Buy Now & Get Exclusive Discount on this Report, Checkout link @
https://www.thebusinessresearchcompany.com/Discount?id=7781&type=discount

Major companies operating in the specialty generics market report are Teva Pharmaceutical Industries Ltd., Endo International plc, Akorn Operating Company LLC , Mylan NV, Mallinckrodt Pharmaceuticals, Dr. Reddy's Laboratories Ltd., Apotex Corp., Fresenius Kabi Brasil Ltda, STADA Arzneimittel AG, Cipla Limited, Lupin Ltd, Aurobindo Pharma Limited, Aspen Pharmacare Holdings Limited, Pfizer Inc., Accord Healthcare Limited, Amneal Pharmaceuticals Inc., Sandoz International GmbH, Zydus Lifesciences Ltd., Torrent Pharmaceuticals Ltd., Perrigo Company plc, Impax Laboratories Inc., Par Pharmaceutical Companies Inc., Alvogen, Alkem Laboratories Ltd., Wockhardt Ltd., Strides Pharma Science Limited, Indoco Remedies Ltd., Unichem Laboratories Ltd., Alembic Pharmaceuticals Ltd., Jubilant Life Sciences Ltd.

Contents of the report:
1. Executive Summary
2. Specialty Generics Market Report Structure
3. Specialty Generics Market Trends And Strategies
4. Specialty Generics Market - Macro Economic Scenario
5. Specialty Generics Market Size And Growth
…..
27. Specialty Generics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix

Explore the report store to make a direct purchase of the report @
https://www.thebusinessresearchcompany.com/report/specialty-generics-global-market-report

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ"

Learn More About The Business Research Company
The Business Research Company (www.thebusinessresearchcompany.com) is a leading market intelligence firm renowned for its expertise in company, market, and consumer research. With a global presence, TBRC's consultants specialize in diverse industries such as manufacturing, healthcare, financial services, chemicals, and technology, providing unparalleled insights and strategic guidance to clients worldwide.

This release was published on openPR.